Antonio Toscano

Italian Journal of Anatomy and Embryology - contenuto non piu disponibile

Alba Migliorato, Daniela Parisi, Olimpia Musumeci, Federica Montagnese et autres

Pompe disease is an inherited metabolic multisystemic disorder resulting in glycogen storage in different tissues, caused by a deficiency of the lysosomal enzyme acid alfa-glucosidase. Glycogen storage is often a morphological marker in muscle biopsy of Pompe patients but it could be …

Clinical, laboratory, and radiological features influencing admission DWI-ASPECTS in stroke patients with middle cerebral artery occlusion undergoing mechanical thrombectomy

Carmelo Tiberio Currò, Antonio Ciacciarelli, Giulia Fiume, Davide Vicari et autres

BACKGROUND AND AIM: The Diffusion-Weighted Imaging Alberta Stroke Programme Early Computed Tomography Score (DWI-ASPECTS) is a rapid and practical score used for quantifying the extent of early ischemic changes in acute ischemic stroke. It is strongly associated with stroke prognosis. The present …

it (code pays fourni par la source)

Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke: Rationale and Study Protocol of a Multicenter, Randomized, Proof-of-Concept, Phase 2a/b Trial in Patients Treated With Mechanical Thrombectomy (DOWN-SUITE)

F. Pedrazzini, Lorenzo Piergallini, Susanna Diamanti, Enrico Fainardi et autres

BACKGROUND: Collateral blood flow is a critical determinant of successful recanalization in acute ischemic stroke caused by large vessel occlusion. Head down tilt -15° (HDT15), similar to Trendelenburg positioning, is a simple, low-cost positional therapy that may augment cerebral collateral blood flow …

it, fr, gb (code pays fourni par la source)

Clinical and therapeutic clues from a long-term follow-up: a single center experience on a large LOPD population

Alessia Pugliese, Mattia Porcino, Selene Francesca Anna Drago, Giuseppe Trimarchi et autres

it (code pays fourni par la source)

Patient-reported outcomes from the COMET trial comparing avalglucosidase alfa and alglucosidase alfa: a plain language summary

Antonio Toscano, Benedikt Schoser, Raymond Saich, Kenneth I. Berger et autres

Plain Language SummaryWhat is this summary about?This is a plain language summary of an article originally published in the journal Molecular Genetics and Metabolism. Pompe disease is a rare disease that runs in families. It can have severe symptoms and impact the …

de, us (code pays fourni par la source)

Long-term safety outcomes and patient preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and Mucopolysaccharidosis Type I (MPS-I): final results of two-year observation

Antonio Toscano, Olimpia Musumeci, Michele Sacchini, Sabrina Ravaglia et autres

Abstract Background Pompe disease and Mucopolysaccharidoses Type I (MPS-I) are lysosomal disorders caused by a deficiency of α-glucosidase and alpha-L-iduronidase, respectively. The mainstay of treatment is enzyme replacement therapy (ERT), a life-long treatment that requires regular I.V. infusions. Hospital-based therapy can, however, …

it (code pays fourni par la source)

Long-term safety outcomes and patient preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and Mucopolysaccharidosis Type I (MPS-I): final results of two-year observation

Antonio Toscano, Olimpia Musumeci, Michele Sacchini, Sabrina Ravaglia et autres

Abstract Background Pompe disease and Mucopolysaccharidoses Type I (MPS-I) are lysosomal disorders caused by a deficiency of α-glucosidase and alpha-L-iduronidase, respectively. The mainstay of treatment is enzyme replacement therapy (ERT), a life-long treatment that requires regular I.V. infusions. Hospital-based therapy can, however, …

it (code pays fourni par la source)

Additional file 1 of Long-term safety outcomes and patient preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and Mucopolysaccharidosis Type I (MPS-I): final results of two-year observation

Antonio Toscano, Olimpia Musumeci, Michele Sacchini, Sabrina Ravaglia et autres

Supplementary Material 1

it (code pays fourni par la source)

Additional file 1 of Long-term safety outcomes and patient preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and Mucopolysaccharidosis Type I (MPS-I): final results of two-year observation

Antonio Toscano, Olimpia Musumeci, Michele Sacchini, Sabrina Ravaglia et autres

Supplementary Material 1

it (code pays fourni par la source)

3024 COMET post hoc analysis: efficacy of long-term avalglucosidase alfa in subgroups of patients with late-onset Pompe disease

Robert D. Henderson, Antonio Toscano, Priya S. Kishnani, Mazen M. Dimachkie et autres

Objective Explore the effects of baseline characteristics on long-term safety/efficacy of avalglucosidase alfa (AVA) in subgroups of patients with late-onset Pompe disease enrolled in COMET (Phase 3; NCT02782741).Methods COMET randomised treatment-naïve patients to AVA (n=51) or alglucosidase alfa (ALG; n=49). After a …

au, it, us, fr, gb, jp, kr, br, de (code pays fourni par la source)

Multicenter, non-interventional, double cohort study to assess the safety of alglucosidase alfa and laronidase in real-world home infusion setting

Antonio Toscano, Maurizio Scarpa, Rossella Parini, A Donati et autres

it (code pays fourni par la source)

The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks

Priya S. Kishnani, Jordi Díaz‐Manera, Hani Kushlaf, Shafeeq Ladha et autres

us, gb, it, nl, tw, ru, fr, kr, tr, pl, de (code pays fourni par la source)